Aldeyra Dry Eye Drug Hits Major Trial Goal, FDA Application Resubmitted After Previous Rejection

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only new clinical data included in the resubmitted NDA were from the recently completed dry eye chamber trial, which achieved the primary endpoint.

https://www.stocktitan.net/news/ALDX/aldeyra-therapeutics-resubmits-reproxalap-new-drug-application-for-a835pf86md8q.html